Search

Your search keyword '"Richie, Thomas L."' showing total 499 results

Search Constraints

Start Over You searched for: Author "Richie, Thomas L." Remove constraint Author: "Richie, Thomas L."
499 results on '"Richie, Thomas L."'

Search Results

2. PfSPZ-CVac malaria vaccine demonstrates safety among malaria-experienced adults: A randomized, controlled phase 1 trial

4. Diagnostic performance and comparison of ultrasensitive and conventional rapid diagnostic test, thick blood smear and quantitative PCR for detection of low-density Plasmodium falciparum infections during a controlled human malaria infection study in Equatorial Guinea

5. A PfSPZ vaccine immunization regimen equally protective against homologous and heterologous controlled human malaria infection

6. Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial

7. Innate immune activation restricts priming and protective efficacy of the radiation-attenuated PfSPZ malaria vaccine

8. Implementation of a Randomized, Placebo-Controlled Trial of Live Attenuated Malaria Sporozoite Vaccines in an Indonesian Military Study Population

9. Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial

10. Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity

11. Safety and protective efficacy of PfSPZ Vaccine administered to HIV-negative and -positive Tanzanian adults

12. Protection from Malaria after Pre-Conception PfSPZ Vaccine

13. OA-722 Assessment of naturally acquired humoral immunity against malaria protecting against controlled human malaria infection (CHMI)

14. Incidence of Plasmodium falciparum malaria infection in 6-month to 45-year-olds on selected areas of Bioko Island, Equatorial Guinea

15. Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial

16. Piloting delivery of PfSPZ vaccines for malaria through a cryogenic vaccine cold chain to travel and military medicine clinics.

18. Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection

19. Safety and Immunogenicity of Radiation-Attenuated PfSPZ Vaccine in Equatoguinean Infants, Children, and Adults

20. Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial

23. Plasmodium 18S rRNA biomarker clearance after FDA-approved antimalarial treatment in controlled human malaria infection trials

26. PfSPZ Vaccine Does Not Increase Biomarkers of Epstein-Barr Virus Reactivation Predictive of Endemic Burkitt Lymphoma

27. A randomized controlled trial showing safety and efficacy of a whole sporozoite vaccine against endemic malaria

28. Increased levels of anti-PfCSP antibodies in post-pubertal females versus males immunized with PfSPZ Vaccine does not translate into increased protective efficacy

29. Plasmodium 18S Ribosomal RNA Biomarker Clearance After Food and Drug Administration–Approved Antimalarial Treatment in Controlled Human Malaria Infection Trials.

30. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination

31. Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine

33. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine

34. The impact of Loa loa microfilaraemia on research subject retention during a whole sporozoite malaria vaccine trial in Equatorial Guinea

35. Multi-Dose Priming Regimens of PfSPZ Vaccine: Safety and Efficacy against Controlled Human Malaria Infection in Equatoguinean Adults

36. A First for Human Vaccinology: GMP Compliant Radiation Attenuation of Plasmodium falciparum Sporozoites for Production of a Vaccine Against Malaria

37. Additional file 1 of Diagnostic performance and comparison of ultrasensitive and conventional rapid diagnostic test, thick blood smear and quantitative PCR for detection of low-density Plasmodium falciparum infections during a controlled human malaria infection study in Equatorial Guinea

41. Genome, proteome, and immunome data explain why 6 month controlled human malaria infection with sporozoites of the Pf7G8 clone of Plasmodium falciparum is a rigorous predictor of the efficacy of the PfNF54-based PfSPZ Vaccine in Africa

42. Diagnostic Performance and Comparison of Ultrasensitive and Conventional Rapid Diagnostic Test, Thick Blood Smear and Quantitative PCR for Detection of Low-Density Plasmodium Falciparum Infections During a Controlled Human Malaria Infection Study in Equatorial Guinea

43. Sporozoite immunization: innovative translational science to support the fight against malaria.

46. A three-antigen Plasmodium falciparum DNA prime—Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults

47. IMRAS—Immunization with radiation-attenuated Plasmodium falciparum sporozoites by mosquito bite: Cellular immunity to sporozoites, CSP, AMA1, TRAP and CelTOS

48. Beyond Blood Smears: Qualification of Plasmodium 18S rRNA as a Biomarker for Controlled Human Malaria Infections

Catalog

Books, media, physical & digital resources